United States Ibrutinib Market Report 2017

November 2017 | 101 pages | ID: U6F8CE336E3WEN
QYResearch

Abstracts

In this report, the United States Ibrutinib market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Ibrutinib in these regions, from 2012 to 2022 (forecast).

United States Ibrutinib market competition by top manufacturers/players, with Ibrutinib sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Pharmacyclics, Inc.
• Janssen Biotech, Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Table
• Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Ibrutinib for each application, including

• Chronic Lymphocytic Leukaemia (CLL)
• Mantle Cell Lymphoma (MCL)
• Diffuse Large B Cell Lymphoma (DLBCL)
• Multiple Myeloma (MM)
• Follicular Lymphoma (FL)

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Ibrutinib Market Report 2017

1 IBRUTINIB OVERVIEW

1.1 Product Overview and Scope of Ibrutinib
1.2 Classification of Ibrutinib by Product Category
  1.2.1 United States Ibrutinib Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Ibrutinib Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Table
  1.2.4 Other
1.3 United States Ibrutinib Market by Application/End Users
  1.3.1 United States Ibrutinib Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Chronic Lymphocytic Leukaemia (CLL)
  1.3.3 Mantle Cell Lymphoma (MCL)
  1.3.4 Diffuse Large B Cell Lymphoma (DLBCL)
  1.3.5 Multiple Myeloma (MM)
  1.3.6 Follicular Lymphoma (FL)
1.4 United States Ibrutinib Market by Region
  1.4.1 United States Ibrutinib Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Ibrutinib Status and Prospect (2012-2022)
  1.4.3 Southwest Ibrutinib Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Ibrutinib Status and Prospect (2012-2022)
  1.4.5 New England Ibrutinib Status and Prospect (2012-2022)
  1.4.6 The South Ibrutinib Status and Prospect (2012-2022)
  1.4.7 The Midwest Ibrutinib Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Ibrutinib (2012-2022)
  1.5.1 United States Ibrutinib Sales and Growth Rate (2012-2022)
  1.5.2 United States Ibrutinib Revenue and Growth Rate (2012-2022)

2 UNITED STATES IBRUTINIB MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Ibrutinib Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Ibrutinib Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Ibrutinib Average Price by Players/Suppliers (2012-2017)
2.4 United States Ibrutinib Market Competitive Situation and Trends
  2.4.1 United States Ibrutinib Market Concentration Rate
  2.4.2 United States Ibrutinib Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Ibrutinib Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES IBRUTINIB SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Ibrutinib Sales and Market Share by Region (2012-2017)
3.2 United States Ibrutinib Revenue and Market Share by Region (2012-2017)
3.3 United States Ibrutinib Price by Region (2012-2017)

4 UNITED STATES IBRUTINIB SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Ibrutinib Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Ibrutinib Revenue and Market Share by Type (2012-2017)
4.3 United States Ibrutinib Price by Type (2012-2017)
4.4 United States Ibrutinib Sales Growth Rate by Type (2012-2017)

5 UNITED STATES IBRUTINIB SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Ibrutinib Sales and Market Share by Application (2012-2017)
5.2 United States Ibrutinib Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES IBRUTINIB PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Pharmacyclics, Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Ibrutinib Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Pharmacyclics, Inc. Ibrutinib Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Janssen Biotech, Inc.
  6.2.2 Ibrutinib Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Janssen Biotech, Inc. Ibrutinib Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview

7 IBRUTINIB MANUFACTURING COST ANALYSIS

7.1 Ibrutinib Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Ibrutinib

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Ibrutinib Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Ibrutinib Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES IBRUTINIB MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Ibrutinib Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Ibrutinib Sales Volume Forecast by Type (2017-2022)
11.3 United States Ibrutinib Sales Volume Forecast by Application (2017-2022)
11.4 United States Ibrutinib Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Ibrutinib
Figure United States Ibrutinib Market Size (K MT) by Type (2012-2022)
Figure United States Ibrutinib Sales Volume Market Share by Type (Product Category) in 2016
Figure Table Product Picture
Figure Other Product Picture
Figure United States Ibrutinib Market Size (K MT) by Application (2012-2022)
Figure United States Sales Market Share of Ibrutinib by Application in 2016
Figure Chronic Lymphocytic Leukaemia (CLL) Examples
Table Key Downstream Customer in Chronic Lymphocytic Leukaemia (CLL)
Figure Mantle Cell Lymphoma (MCL) Examples
Table Key Downstream Customer in Mantle Cell Lymphoma (MCL)
Figure Diffuse Large B Cell Lymphoma (DLBCL) Examples
Table Key Downstream Customer in Diffuse Large B Cell Lymphoma (DLBCL)
Figure Multiple Myeloma (MM) Examples
Table Key Downstream Customer in Multiple Myeloma (MM)
Figure Follicular Lymphoma (FL) Examples
Table Key Downstream Customer in Follicular Lymphoma (FL)
Figure United States Ibrutinib Market Size (Million USD) by Region (2012-2022)
Figure The West Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Ibrutinib Sales (K MT) and Growth Rate (2012-2022)
Figure United States Ibrutinib Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Ibrutinib Market Major Players Product Sales Volume (K MT) (2012-2017)
Table United States Ibrutinib Sales (K MT) of Key Players/Suppliers (2012-2017)
Table United States Ibrutinib Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Ibrutinib Sales Share by Players/Suppliers
Figure 2017 United States Ibrutinib Sales Share by Players/Suppliers
Figure United States Ibrutinib Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Ibrutinib Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Ibrutinib Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Ibrutinib Revenue Share by Players/Suppliers
Figure 2017 United States Ibrutinib Revenue Share by Players/Suppliers
Table United States Market Ibrutinib Average Price (USD/MT) of Key Players/Suppliers (2012-2017)
Figure United States Market Ibrutinib Average Price (USD/MT) of Key Players/Suppliers in 2016
Figure United States Ibrutinib Market Share of Top 3 Players/Suppliers
Figure United States Ibrutinib Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Ibrutinib Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Ibrutinib Product Category
Table United States Ibrutinib Sales (K MT) by Region (2012-2017)
Table United States Ibrutinib Sales Share by Region (2012-2017)
Figure United States Ibrutinib Sales Share by Region (2012-2017)
Figure United States Ibrutinib Sales Market Share by Region in 2016
Table United States Ibrutinib Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Ibrutinib Revenue Share by Region (2012-2017)
Figure United States Ibrutinib Revenue Market Share by Region (2012-2017)
Figure United States Ibrutinib Revenue Market Share by Region in 2016
Table United States Ibrutinib Price (USD/MT) by Region (2012-2017)
Table United States Ibrutinib Sales (K MT) by Type (2012-2017)
Table United States Ibrutinib Sales Share by Type (2012-2017)
Figure United States Ibrutinib Sales Share by Type (2012-2017)
Figure United States Ibrutinib Sales Market Share by Type in 2016
Table United States Ibrutinib Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Ibrutinib Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Ibrutinib by Type (2012-2017)
Figure Revenue Market Share of Ibrutinib by Type in 2016
Table United States Ibrutinib Price (USD/MT) by Types (2012-2017)
Figure United States Ibrutinib Sales Growth Rate by Type (2012-2017)
Table United States Ibrutinib Sales (K MT) by Application (2012-2017)
Table United States Ibrutinib Sales Market Share by Application (2012-2017)
Figure United States Ibrutinib Sales Market Share by Application (2012-2017)
Figure United States Ibrutinib Sales Market Share by Application in 2016
Table United States Ibrutinib Sales Growth Rate by Application (2012-2017)
Figure United States Ibrutinib Sales Growth Rate by Application (2012-2017)
Table Pharmacyclics, Inc. Basic Information List
Table Pharmacyclics, Inc. Ibrutinib Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Pharmacyclics, Inc. Ibrutinib Sales Growth Rate (2012-2017)
Figure Pharmacyclics, Inc. Ibrutinib Sales Market Share in United States (2012-2017)
Figure Pharmacyclics, Inc. Ibrutinib Revenue Market Share in United States (2012-2017)
Table Janssen Biotech, Inc. Basic Information List
Table Janssen Biotech, Inc. Ibrutinib Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2012-2017)
Figure Janssen Biotech, Inc. Ibrutinib Sales Growth Rate (2012-2017)
Figure Janssen Biotech, Inc. Ibrutinib Sales Market Share in United States (2012-2017)
Figure Janssen Biotech, Inc. Ibrutinib Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Ibrutinib
Figure Manufacturing Process Analysis of Ibrutinib
Figure Ibrutinib Industrial Chain Analysis
Table Raw Materials Sources of Ibrutinib Major Players/Suppliers in 2016
Table Major Buyers of Ibrutinib
Table Distributors/Traders List
Figure United States Ibrutinib Sales Volume (K MT) and Growth Rate Forecast (2017-2022)
Figure United States Ibrutinib Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Ibrutinib Price (USD/MT) Trend Forecast (2017-2022)
Table United States Ibrutinib Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Ibrutinib Sales Volume (K MT) Forecast by Type (2017-2022)
Figure United States Ibrutinib Sales Volume (K MT) Forecast by Type in 2022
Table United States Ibrutinib Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Ibrutinib Sales Volume (K MT) Forecast by Application (2017-2022)
Figure United States Ibrutinib Sales Volume (K MT) Forecast by Application in 2022
Table United States Ibrutinib Sales Volume (K MT) Forecast by Region (2017-2022)
Table United States Ibrutinib Sales Volume Share Forecast by Region (2017-2022)
Figure United States Ibrutinib Sales Volume Share Forecast by Region (2017-2022)
Figure United States Ibrutinib Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources